Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway

Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway

Choice of direct acting antiviral (DAA) therapy for Hepatitis C Virus (HCV) in the United Kingdom and similar settings usually requires knowledge of the genotype and, in some cases, antiviral resistance (AVR) profile of the infecting virus. To determine these, most laboratories currently use Sanger...

Full description

Bibliographic Details
Main Authors: Carmen F. Manso, David F. Bibby, Kieren Lythgow, Hodan Mohamed, Richard Myers, David Williams, Renata Piorkowska, Yuen T. Chan, Rory Bowden, M. Azim Ansari, Camilla L. C. Ip, Eleanor Barnes, Daniel Bradshaw, Jean L. Mbisa
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Microbiology
Subjects:
hepatitis C virus
antiviral resistance
genotyping
whole genome sequencing
next generation sequencing
direct acting antivirals
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.576572/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2020.576572/full

Similar Items